HC Wainwright Has Bullish Estimate for CORT FY2026 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for shares of Corcept Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $3.99 for the year, up from their prior estimate of $3.80. HC Wainwright currently has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ FY2027 earnings at $7.46 EPS, FY2028 earnings at $9.29 EPS and FY2029 earnings at $11.10 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $181.89 million during the quarter, compared to analyst estimates of $200.12 million.

Other equities research analysts have also issued reports about the company. Truist Financial upped their price objective on Corcept Therapeutics from $76.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a research report on Tuesday. StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Piper Sandler upped their target price on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $143.25.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $74.45 on Thursday. The firm has a market capitalization of $7.85 billion, a PE ratio of 59.09 and a beta of 0.14. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $117.33. The firm has a 50-day moving average price of $64.81 and a 200 day moving average price of $56.28.

Insider Buying and Selling at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Joseph K. Belanoff sold 2,924 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $60.91, for a total value of $178,100.84. Following the transaction, the chief executive officer now directly owns 3,019,411 shares in the company, valued at approximately $183,912,324.01. This represents a 0.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 163,124 shares of company stock worth $15,074,318. 20.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CORT. Synergy Asset Management LLC lifted its holdings in Corcept Therapeutics by 131.3% in the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after buying an additional 262,503 shares during the period. Van ECK Associates Corp bought a new stake in shares of Corcept Therapeutics during the 4th quarter valued at $4,483,000. State Street Corp lifted its stake in shares of Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after purchasing an additional 19,893 shares during the period. Burney Co. boosted its position in shares of Corcept Therapeutics by 9.1% in the 4th quarter. Burney Co. now owns 473,821 shares of the biotechnology company’s stock worth $23,876,000 after purchasing an additional 39,657 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Corcept Therapeutics by 43.4% during the third quarter. JPMorgan Chase & Co. now owns 253,070 shares of the biotechnology company’s stock worth $11,712,000 after purchasing an additional 76,573 shares during the period. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.